Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RITUXILUP
2012-004893-25Phase 3Completed
- Sponsor
- Imperial College London
- Start
- May 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, mycophenolate mofetil and prednisolone in lupus nephritis (LN) (2 arms), sponsored by Imperial College London. Primary endpoint: Complete renal response at week 52. Started May 2014; status: completed.
02
Drugs
rituximabmycophenolate mofetilprednisolone
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2012-004893-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004893-25.